Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
HOME > REGULATORY
REGULATORY
- EMA Recommends Approval for Fixed-Dose Combination of Canagliflozin, Metformin
February 27, 2014
- Cabinet OKs Bill to Merge NIBIO, NIHN to Create New Institute
February 26, 2014
- PAFSC’s First Committee Supports Approval of Novel Antiplatelet Agent Prasugrel
February 25, 2014
- Penalty for Lengthy Drug Delivery Talks Will Lift Price Settlement Rates: Minister
February 25, 2014
- MHLW May Take Harsh Action against Novartis over Diovan Raids: Minister Tamura
February 25, 2014
- LDP Closes Discussions on Fee Cuts to Be Imposed on Hospitals, Pharmacies with Low Price Settlement Rates
February 25, 2014
- MHLW to Set Up Complaint Hotline for Hospitals, Pharmacies Upon Introduction of Penalty for Low Price Settlement Rates
February 25, 2014
- Astellas Unit, 12 Others Prequalified for Expedited Product Importation under FDA Pilot Program
February 21, 2014
- PFSB Issues Director Notification Calling for Revision of Package Inserts for Products Including Kiklin, Stivarga
February 20, 2014
- Tokyo Prosecutors Raid Novartis Japan Office over Diovan Ads
February 20, 2014
- Penalty for Lengthy Drug Price Haggling – Interview 1: “It Can’t Be Helped” Says Idaikyo Exec Koyama
February 19, 2014
- MHLW to Form Panel to Combat Counterfeit Drugs
February 19, 2014
- Deputy Director Masuyama of ELD Stresses Need to Establish Separate Guidelines for Different Biosimilars at SRSM Symposium
February 19, 2014
- PAFSC Second Committee to Discuss H5N1 Vaccines on Feb. 28
February 18, 2014
- “Politicians Should Not Intervene” in Dispute Over Rule to Reduce Medical Fees Claimed: Parliamentary Secretary of Health
February 18, 2014
- 34 Firms Win Approval for Diovan Generics, 31 for Preminent Generics towards June Listing
February 17, 2014
- Diet Begins Discussions on 2 Bills Related to Establishment of “Japanese NIH,” Aimed at Commercialization of Innovative New Drugs
February 17, 2014
- Joint Purchasing May Rise as Hospitals with Low Settlement Rates Face Cuts in Fees Claimed: Chuikyo Member
February 17, 2014
- Kaketsuken Makes Another Bid to Fill Unmet Flu Vaccine Quota for 25 Million People
February 14, 2014
- FY2014 Medical Fee Revision to Limit Premium for Atypical Antipsychotics to Prescriptions with 2 or Fewer Drugs
February 14, 2014
ページ
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…